

Contents

Results Reviews

- **ITC:** ITC reported a weak operating print due to a soft cigarette performance along with sustained weakness seen in the agri and paper portfolio. Cigarette net revenue/EBIT growth was at 4/2%, with volume estimated to have fallen by 1% (5% 4-year CAGR) on a high base. Differentiated and premium offerings continued to perform well. With the base now catching up, we model cigarette revenue/EBIT growth of 7% over FY23-FY26. FMCG continued to report a resilient performance in a difficult environment with revenue growing by 8% (+13% on 2-year CAGR) while EBITDAM expanded by 100bps to 11%. Paper performance remained impacted by low-priced Chinese supplies, muted domestic demand and a sharp drop in realisations. Hotel revenue was up by 18%. ITC's overall revenue grew 2% while EBITDA fell 3% YoY. The recent stock run-up (~30% in LTM) and limited earnings surprise scope given a higher base further restrict rerating potential. We cut our estimates by 1% over FY24-26 to reflect Q3 performance and value ITC on a SoTP basis to derive a TP of INR 460. The implied target P/E is 24x Dec-25E EPS. Maintain ADD.
- Bajaj Finance: Bajaj Finance (BAF) delivered a mixed set of earnings with robust AUM growth (+35% YoY) despite a regulatory embargo on select products and stable NIMs (11.3%), offset by elevated credit costs (1.8% annualised). BAF extended its long-range strategy (LRS) to FY28, guiding for 22-27% AUM CAGR and 20-25% earnings CAGR over FY24-FY28E. On the back of its omnichannel strategy, the widest product suite and focus on crosssell, we believe BAF is poised for ~23% AUM CAGR in the medium-term, while also simultaneously delivering steady profitability. We tweak our earnings by ~2% for FY24E-FY26E to reflect stronger AUM growth, offset by higher credit costs; we maintain BUY with a revised RI-based TP of INR8,690 (implied 26x Sep-25 EPS; 5.4x Sep-25 ABVPS).
- Cholamandalam Investment and Finance Company: Chola reported healthy operating metrics with strong AUM growth and sustained NIMs, partially offset by higher opex intensity and credit costs. LAP (+35% YoY), home loans (+66% YoY) and new businesses (+120% YoY) continued to drive overall AUM growth (+40% YoY), driven primarily by increasing penetration of these products in existing branches. While Chola remains a prolific franchise with medium-term RoEs of ~20%+, we expect moderation in loan growth going ahead and subsequently limited upside in stock from current levels. We tweak our earnings estimates to build in higher AUM growth for FY24, offset by higher opex intensity and maintain ADD with a revised RI-based TP of INR1285 (implying 4.6x Sep-25 ABVPS).
- Gail (India): Our BUY recommendation on GAIL with a target price of INR 185 is based on (1) an increase in gas transmission volume to 130mmscmd by FY25 on the back of an increase in domestic gas production, (2) completion of major pipelines in eastern and southern India, and (3) expectation of improvement in earnings from the petchem segment. Q3FY24 reported EBITDA/PAT at INR 38/28bn, which came in above our estimates, driven by higher natural gas marketing margins and improvement in petchem segment earnings. Higher-than-expected other income of INR 8bn (+18% YoY, +45% QoQ) also supported earnings. Depreciation was at INR 7.8bn (+26% YoY, +4.5% QoQ) and interest cost at INR 1.6bn, (+49% YoY, -9% QoQ).

HSIE Research Team hdfcsec-research@hdfcsec.com



- Macrotech Developers: Macrotech Developers Ltd (MDL) reported strong quarterly presales of INR 34.1bn (+12/-3% YoY/QoQ), with a presales volume of INR 2.6msf (+4/+0% YoY/QoQ). Average price realisation as a result increased to INR 13,115 (+8/-3% YoY/QoQ). MMR/Pune/Bengaluru market saw presales of INR 24.1/3.4/6.6bn. Collections were INR 25.9bn (-3.4/-6% YoY/QoQ). The embedded EBITDA margin on presales was ~30%. On the business development front, MDL added GDV worth INR 60bn (INR 203bn in 9MFY24, surpassing FY24 guidance of INR 175bn) and a saleable area of 2msf. The implied realisation, as a result, is INR 30,000/sq. ft. MDL saw a strong launch response for its first project in Bengaluru, selling out ~90% worth INR6.6bn with a second project likely in Q4FY24. The IRR threshold for the Bengaluru project is marked at 20%. In terms of launches, INR 63bn worth of launches are planned for the rest of FY24 with a saleable area of 4.4msf. In terms of price hikes, since Apr'23, MDL has hiked prices by 4% and expects full-year price appreciation of 6-7%. Given robust growth visibility, betterthan-expected GDV addition and uptick in land prices (Palava may see price and volume increase as new infra projects get commissioned over the next few years), we increase our TP to INR 1,111/sh. Owing to the limited upside on our TP, we maintain our ADD rating.
- Marico: Marico's consolidated revenue fell 2% YoY as price cuts continue to impact revenue growth. Domestic revenue is down 3% with volume growth of 2% (5% four-year CAGR). Corrective steps taken to alleviate RoI challenges faced by channel partners impacted volumes in Q3. While rural demand and mass segments continued to remain soft, urban demand sustained its moderate growth trajectory. The international business posted 6% CC (2% reported) dragged by transient macro headwinds in Bangladesh as other regions delivered resilient performances. Softening inflation and a favourable mix enabled GM expansion of 635bps YoY to 51.3%, a part of which was reinvested through higher A&P spending (up 12% YoY). As a result, EBITDA grew by 13% YoY while margins expanded by 270bps to 21%. Marico remains on track for an EBITDAM expansion of 250bps in FY24. With improving macros and the anniversary of price cuts on the horizon, we continue to build in gradual recovery in volumes in coming quarters. We model a 12% EBITDA CAGR during FY23-26E. We prefer Marico, given its thrust to drive growth in its core brands, initiatives to drive D2C/foods, and the margin upcycle. We value the stock at 45x on Dec-25 EPS to derive a target price of INR 650. Maintain ADD.



ITC Weak quarter

ITC reported a weak operating print due to a soft cigarette performance along with sustained weakness seen in the agri and paper portfolio. Cigarette net revenue/EBIT growth was at 4/2%, with volume estimated to have fallen by 1% (5% 4-year CAGR) on a high base. Differentiated and premium offerings continued to perform well. With the base now catching up, we model cigarette revenue/EBIT growth of 7% over FY23-FY26. FMCG continued to report a resilient performance in a difficult environment with revenue growing by 8% (+13% on 2-year CAGR) while EBITDAM expanded by 100bps to 11%. Paper performance remained impacted by low-priced Chinese supplies, muted domestic demand and a sharp drop in realisations. Hotel revenue was up by 18%. ITC's overall revenue grew 2% while EBITDA fell 3% YoY. The recent stock run-up (~30% in LTM) and limited earnings surprise scope given a higher base further restrict rerating potential. We cut our estimates by 1% over FY24-26 to reflect Q3 performance and value ITC on a SoTP basis to derive a TP of INR 460. The implied target P/E is 24x Dec-25E EPS. Maintain ADD.

- FMCG/hotel momentum sustains; cigarette soft on a high base: Overall revenue grew by 2% YoY as 4/8/18% growth in cigarettes (net)/FMCG/hotels was partially offset by a 2/10% decline in the agri and paper segments. Cigarette volume fell 1% YoY on a high base (4-year CAGR at 5%). FMCG saw resilient performance growing by 8% (+13% 2-year CAGR) despite a challenging demand environment. Growth was seen in both traditional and emerging channels. Hotels' performance was led by strong ARRs and occupancies across properties, driven by retail, MICE segments and the ICC Cricket World Cup. Paper revenue continued to remain impacted by low-priced Chinese supplies in global markets and muted domestic demand. Ex of wheat and rice exports, the agribusiness grew 14% YoY, driven by value-added agri products and lead tobacco. We model 7% consolidated revenue CAGR for FY23-26E.
- Soft operating print: The cigarette/FMCG/hotel EBIT grew at 2/24/57% YoY. While agri EBIT fell 13%, paper EBIT fell 51% due to a sharp drop in realisations and an unprecedented surge in domestic wood costs. As a result, overall EBITDA fell 3% YoY. FMCG EBITDA margin expanded by 100bps YoY to 11%, led by premiumisation, supply chain optimisation, pricing actions, digital initiatives, strategic cost management and fiscal incentives. We model a 7% EBITDA CAGR for FY23-26.
- Other takeaways: (1) Within FMCG, competitive intensity remained high in certain categories such as biscuits, snacks, noodles, and popular soaps, including from local/regional players. (2) Within cigarettes, the focus is on innovation and democratising premiumisation across segments. (3) Within paper, global demand remains subdued. Domestic recovery in slow postfestive season. (4) A facility to manufacture and export nicotine and nicotine derivative products has been commissioned. Shipments are to commence from Q4FY24. (5) Hotel demerger has received stock exchange approval.

	Q3	Q3	YoY	Q2	QoQ	FY22	FY23	FY24E	FY25E	FY26E
(INR mn)	FY24	FY23	(%)	FY24	(%)	F122	F 1 23	Г I 24E	F125E	F120E
Net Sales	1,76,519	1,72,655	2.2	1,77,051	(0.3)	6,06,681	7,09,369	7,26,435	7,95,078	8,64,359
EBITDA	60,243	62,232	(3.2)	60,416	(0.3)	2,06,584	2,56,649	2,64,009	2,88,779	3,14,765
APAT	52,135	50,310	3.6	49,270	5.8	1,55,031	1,94,603	2,02,416	2,18,349	2,38,160
EPS (INR)	4.2	4.1	2.48	4.0	5.8	12.6	15.7	16.3	17.6	19.2
P/E (x)						35.8	28.7	27.6	25.6	23.5
EV / EBITDA						25.4	20.5	19.8	18.1	16.5
Core RoCE						43.9	52.3	53.6	58.4	62.5

Click. Invest. Grow. YEARS

ADD

CMP (as on 29	INR 450	
Target Price	INR 460	
NIFTY	21,738	
KEY CHANGES	OLD	NEW
Rating	ADD	ADD
Price Target	INR 460	INR 460
	FY24E	FY25E
EPS %	-1%	-1%

KEY STOCK DATA

Bloomberg code	ITC IN
No. of Shares (mn)	12,479
MCap (INR bn) / (\$ mn)	5,613/68,635
6m avg traded value (INR n	nn) 4,943
52 Week high / low	INR 500/327

STOCK PERFORMANCE (%)

	3M	6M	12M
Absolute (%)	3.7	(4.0)	30.8
Relative (%)	(10.2)	(11.8)	11.3

SHAREHOLDING PATTERN (%)

_	Sep-23	Dec-23
Promoters	0.00	0.00
FIs & Local MFs	41.93	41.99
FPIs	14.31	14.23
Public & Others	43.76	43.78
Pledged Shares	0.00	0.00
Source : BSE		

Pledged shares as % of total shares

Varun Lohchab

varun.lohchab@hdfcsec.com +91-22-6171-7334

Paarth Gala

paarth.gala@hdfcsec.com +91-22-6171-7336

Riddhi Shah

riddhi.shah@hdfcsec.com +91-22-6171-7359

Bajaj Finance

Strong fundamentals support relative resilience

Bajaj Finance (BAF) delivered a mixed set of earnings with robust AUM growth (+35% YoY) despite a regulatory embargo on select products and stable NIMs (11.3%), offset by elevated credit costs (1.8% annualised). BAF extended its long-range strategy (LRS) to FY28, guiding for 22-27% AUM CAGR and 20-25% earnings CAGR over FY24-FY28E. On the back of its omnichannel strategy, the widest product suite and focus on cross-sell, we believe BAF is poised for ~23% AUM CAGR in the medium-term, while also simultaneously delivering steady profitability. We tweak our earnings by ~2% for FY24E-FY26E to reflect stronger AUM growth, offset by higher credit costs; we maintain BUY with a revised RI-based TP of INR8,690 (implied 26x Sep-25 EPS; 5.4x Sep-25 ABVPS).

- Steady NIMs; improving operating efficiency: BAF reported steady NIMs (~11.3%) on the back of reflating yields and strong growth in the B2B segment (+54% YoY), offsetting an uptick in funding costs (7.8%). With rising pressure on the cost of funds, BAF has effected a ~25bps rate hike across its product suite, which is likely to help partly offset the margin pressure. Operating efficiencies continued to improve (C/I at 34%; opex-to-AUM at 4.7%) on the back of higher throughput and increasing contribution from new businesses.
- Marginal worsening of asset quality: GS-III/NS-III deteriorated marginally QoQ to 0.95%/0.37% (H1FY24: 0.91%/0.31%) with GS-II flat at 1.1%. As per management, this is largely emanating from B2C segments (rural and urban), with stress in urban B2C being more transient and incremental credit costs likely to remain rangebound. We argue this is an industry-wide phenomenon, with BAF's risk management likely to emerge relatively more resilient.
- Excellent profitability metrics; maintain BUY: BAF's focus on multi-channel customer acquisition and cross-sell of existing and new products is likely to drive robust medium-term AUM CAGR. Additionally, the relentless focus on throughput and consequent operating efficiency, alongside sustained pricing power in key segments, is likely to help sustain strong profitability.

(INR bn)	Q3FY24	Q3FY23	YoY(%)	Q2FY24	QoQ(%)	FY23	FY24E	FY25E	FY26E
NII	76.6	59.2	29.3	72.0	6.4	229.9	294.7	369.5	455.3
PPOP	61.4	48.5	26.6	58.3	5.3	187.2	237.2	301.0	375.0
PAT	36.4	29.7	22.3	35.5	2.4	115.1	144.8	184.8	225.6
EPS (INR)	59.2	49.0	20.9	58.5	1.3	190.2	234.6	299.6	364.7
ROAE (%)						23.5%	22.2%	21.9%	22.0%
ROAA (%)						4.7%	4.6%	4.6%	4.6%
ABVPS (INR)						885	1,215	1,463	1,781
P/ABV (x)						8.1	5.9	4.9	4.0
P/E (x)						37.8	30.6	24.0	19.7

Financial summary (Consolidated)

Change in estimates

INR bn		FY24E			FY25E			FY26E	
INK DR	Old	New	Chg	Old	New	Chg	Old	New	Chg
AUM	3,154	3,259	3.3%	3,891	4,021	3.3%	4,794	4,956	3.4%
NIM (%)	10.0	10.3	24bps	10.1	10.1	3bps	10.1	10.1	0bps
NII	282.4	294.7	4.3%	356.4	369.5	3.7%	440.5	455.3	3.3%
PPOP	227.2	237.2	4.4%	292.5	301.0	2.9%	363.8	375.0	3.1%
PAT	143.0	144.8	1.2%	179.9	184.8	2.7%	220.4	225.6	2.4%
ABVPS (INR)	1,213	1,215	0.1%	1,455	1,463	0.6%	1,767	1,781	0.8%

Source: Company, HSIE Research

HDFC securities Click. Invest. Grow. YEARS

BUY

CMP (as on 29 Jan 2024)	INR 7,192
Target Price	INR 8,690
NIFTY	21,738

KEY CHANGES	OLD	NEW
Rating	BUY	BUY
Price Target	INR8650	INR 8690
EPS %	FY24E	FY25E
EI 3 /0	1.2%	2.7%

KEY STOCK DATA

Bloomberg code	BAF IN
No. of Shares (mn)	618
MCap (INR bn) / (\$ mn)	4,445/54,348
6m avg traded value (IN	(R mn) 7,854
52 Week high / low	INR 8,192/5,486

STOCK PERFORMANCE (%)

	3M	6M	12M
Absolute (%)	(4.2)	(2.6)	24.8
Relative (%)	(18.1)	(10.4)	5.3

SHAREHOLDING PATTERN (%)

	Sep-23	Dec-23
Promoters	55.9	54.8
FIs & Local MFs	12.9	14.1
FPIs	20.1	20.9
Public & Others	11.0	10.2
Pledged Shares	-	
Source: BSE		

Pledged shares as % of total shares

Krishnan ASV

venkata.krishnan@hdfcsec.com +91-22-6171-7314

Deepak Shinde

deepak.shinde@hdfcsec.com +91-22-6171-7323

Akshay Badlani

akshay.badlani@hdfcsec.com +91-22-6171-7325

Cholamandalam Investment and Finance Company

Healthy operating performance; priced to perfection

Chola reported healthy operating metrics with strong AUM growth and sustained NIMs, partially offset by higher opex intensity and credit costs. LAP (+35% YoY), home loans (+66% YoY) and new businesses (+120% YoY) continued to drive overall AUM growth (+40% YoY), driven primarily by increasing penetration of these products in existing branches. While Chola remains a prolific franchise with medium-term RoEs of ~20%+, we expect moderation in loan growth going ahead and subsequently limited upside in stock from current levels. We tweak our earnings estimates to build in higher AUM growth for FY24, offset by higher opex intensity and maintain ADD with a revised RI-based TP of INR1285 (implying 4.6x Sep-25 ABVPS).

- Healthy P&L outcomes: Chola's NIM remained flat sequentially (7.4%) with yield reflation across segments offsetting the rising cost of funds. Other income witnessed a spike due to the insurance commission income of INR 1.6bn as Chola received the insurance brokerage license during Q3. Chola's investments in distribution (employees, branches etc.) are reflected in higher opex intensity (~3.7% of AUM annualised) and have aided in improved throughput for several quarters now.
- Improving GS-II/GS-III; provisions treading as per guidance: GS-III/NS-III improved further to 2.8%/1.6% (Q2FY24: 3.0%/1.6%) with GS-II at 3.1% (Q2FY24: 3.2%). Credit costs moderated sequentially to ~125bps (annualised), driven by the vehicle finance segment and are likely to remain within the management guidance of ~1.1-1.2% for FY24. Delinquencies in the CSEL segment have moderated post cautious stance of the management, while the SBPL segment witnessed healthy traction in Q3.
- A diversified portfolio, branch penetration to aid growth albeit some moderation ahead: Chola continued to report stupendous AUM growth (~40% YoY) with all segments firing at a strong pace. While increasing branch penetration of non-vehicle segments (particularly home loans and LAPs) is likely to aid loan growth, we expect moderation in loan growth to ~22-25% going ahead, driven by vehicle finance (~60% of AUM). Further, the rising cost of funds is likely to drive NIMs lower, which may be partially offset by improving operating efficiency.

Financial summary

(INR bn)	Q3FY24	Q3FY23	YoY (%)	Q2FY24	QoQ(%)	FY23	FY24E	FY25E	FY26E
NII	21.7	16.0	35.8	20.2	7.7	63.3	83.0	106.1	131.4
PPOP	15.2	10.8	40.4	14.2	6.7	44.5	58.7	74.7	95.7
PAT	8.8	6.8	28.0	7.6	14.9	26.7	32.9	43.7	56.9
EPS (INR)	10.5	8.3	25.8	9.3	12.7	32.4	39.2	52.1	66.5
ROAE (%)						20.5	19.5	20.4	21.0
ROAA (%)						2.7	2.5	2.6	2.7
ABVPS (INR)						133.9	205.3	244.4	316.8
P/ABV (x)						9.2	6.0	5.0	3.9
P/E (x)						38.0	31.4	23.6	18.5

Change in estimates

INID 1.	FY24E			FY25E			FY26E		
INR bn	Old	New	Chg	Old	New	Chg	Old	New	Chg
AUM	1,353	1,413	4.5%	1,652	1,726	4.4%	2,008	2,099	4.5%
NIM (%)	6.3	6.2	-12bps	6.3	6.2	-10bps	6.4	6.3	-13bps
NII	82.3	83.0	0.8%	102.7	106.1	3.2%	127.6	131.4	3.0%
PPOP	58.6	58.7	0.2%	73.8	74.7	1.1%	94.2	95.7	1.6%
PAT	33.2	32.9	-0.8%	43.0	43.7	1.8%	56.9	56.9	0.1%
ABVPS (INR)	199	205	3.2%	241	244	1.6%	314	317	0.9%

Source: Company, HSIE Research



ADD

CMP (as on 2	INR 1,231	
Target Price	INR 1,285	
NIFTY		21,738
KEY CHANGES	OLD	NEW
Rating	ADD	ADD
Price Target	INR 1,280	INR 1,285
	FY24E	FY25E
EPS %	-0.8%	1.8%

KEY STOCK DATA

Bloomberg code	CIFC IN
No. of Shares (mn)	840
MCap (INR bn) / (\$ mn)	1,033/12,636
6m avg traded value (INR	mn) 2,275
52 Week high / low	INR 1,310/697

STOCK PERFORMANCE (%)

	3M	6M	12M
Absolute (%)	5.4	8.2	73.4
Relative (%)	(8.6)	0.3	53.9

SHAREHOLDING PATTERN (%)

	Sep-23	Dec-23
Promoters	51.4	50.4
FIs & Local MFs	20.0	18.4
FPIs	21.5	24.7
Public & Others	7.0	6.5
Pledged Shares	0.0	
Source: BSE		

Pledged shares as % of total shares

Deepak Shinde

deepak.shinde@hdfcsec.com +91-22-6171-7323

Krishnan ASV

venkata.krishnan@hdfcsec.com +91-22-6171-7314

Akshay Badlani

akshay.badlani@hdfcsec.com +91-22-6171-7325

Gail (India)

Trading and petchem segments aid earnings

Our BUY recommendation on GAIL with a target price of INR 185 is based on (1) an increase in gas transmission volume to 130mmscmd by FY25 on the back of an increase in domestic gas production, (2) completion of major pipelines in eastern and southern India, and (3) expectation of improvement in earnings from the petchem segment. Q3FY24 reported EBITDA/PAT at INR 38/28bn, which came in above our estimates, driven by higher natural gas marketing margins and improvement in petchem segment earnings. Higher-than-expected other income of INR 8bn (+18% YoY, +45% QoQ) also supported earnings. Depreciation was at INR 7.8bn (+26% YoY, +4.5% QoQ) and interest cost at INR 1.6bn, (+49% YoY, - 9% QoQ).

- NG marketing: Marketing volume of 98mmscmd (+9% YoY) and trading margin of INR 2.3/tscm (+5% QoQ) came ahead of estimates, delivering a strong marketing EBITDA of INR 21bn (+6% QoQ). Management has indicated earnings will remain robust from this segment.
- Petchem: Q3 petchem EBITDA came in at INR 2bn the first profit seen in the last six quarters, supported by an improvement in sales volume at 215kT, (+3.3x YoY, +28% QoQ) and an improvement in petchem production at 205kT (+3x YoY, +28% QoQ), implying capacity utilisation of 92%. Realisation continues to remain under pressure at INR 95/kg (-17% YoY, -8% QoQ).
- NG transmission: Reported the highest-ever transmission volume at 121.5mmscmd (+17% YoY, +1% QoQ); however, it came in below estimate, while transmission tariffs came broadly in line at INR 2,393/tscm (+38% YoY, 0.1% QoQ). EBITDA at INR 16bn (+2.2x YoY, -5% QoQ) came in below the estimate, owing to lower-than-expected transmission volumes.
- LPG & Liquid Hydro Carbon: The LPG & LHC segment reported EBITDA at INR 3bn, coming in above our estimate, supported by higher-than-estimated realisations of INR 52/kg (-5% YoY, +22% QoQ).
- Key takeaways: (1) The company has guided a capex of INR ~170bn in FY25: INR 30bn towards the pipeline segment, INR 44bn towards the petchem segment, INR 30bn towards achieving net zero targets, INR 7.5bn towards operational capex and INR 50bn towards equity contribution to JV's/subsidiaries. (2) Management has guided gas transmission volume will improve by 12-13mmscmd over FY25-26. (3) Management expects the petchem segment to break even in FY24 and generate profits in FY25.
- Change in estimates: We increase our FY24/25/26E EPS by +14/+5.5/2.7% to INR 14.6/15.2/15.9 to factor in higher transmission volumes, marketing margins and petchem production delivering a revised TP of INR 185/sh.
- Our SOTP, at INR 185/sh, is based on 10x Mar-25E EV/e for the natural gas, LPG transmission and gas marketing business, 5.5x EV/e for the petchem and LPG/LHC businesses, and INR 49 for investments. The stock is currently trading at 11.3x Mar-25E EPS and 9.2x EV/EBITDA.

Standalone financial summary

YE March (INR bn)	Q3 FY24	Q2 FY24	QoQ (%)	Q3 FY23	YoY (%)	FY22*	FY23*	FY24E*	FY25E*	FY26E*
Revenue	342	318	7.6	354	(3.2)	928	1,457	1,346	1,428	1,465
EBITDA	38	35	9.5	3	1,362.7	152	75	133	138	146
PAT	28	24	18.2	2	1,056.8	123	56	96	100	104
EPS (INR)	4.3	3.7	18.2	0.4	1,056.8	18.6	8.5	14.6	15.2	15.9
P/E (x)						9.2	20.1	11.7	11.3	10.8
EV / EBITDA (x)						8.0	17.5	9.8	9.2	8.5
RoE (%)						20.9	8.7	13.8	12.6	11.6
Source: Company,	HSIE Re	search	*Consol	idated						

HDFC securities Click. Invest. Grow. YEARS

BUY

CMP (as on 29	INR 172	
Target Price	INR 185	
NIFTY		21,738
KEY CHANGES	OLD	NEW
Rating	BUY	BUY
Price Target	INR 145	INR 185
EDS change	FY24E	FY25E
EPS change	+14.2%	+5.5%

KEY STOCK DATA

Bloomberg code	GAIL IN
No. of Shares (mn)	6,575
MCap (INR bn) / (\$ mn)	1,129/13,808
6m avg traded value (INR n	nn) 2,895
52 Week high / low	INR 175/91

STOCK PERFORMANCE (%)

	3M	6M	12M
Absolute (%)	45.2	46.2	73.2
Relative (%)	31.3	38.3	53.7

SHAREHOLDING PATTERN (%)

	Sep-23	Dec-23
Promoters	51.91	51.90
FIs & Local MFs	27.04	27.28
FPIs	14.76	14.24
Public & Others	6.29	6.59
Pledged Shares	0.0	0.0
Source : BSE		

Harshad Katkar

harshad.katkar@hdfcsec.com +91-22-6171-7319

Nilesh Ghuge

nilesh.ghuge@hdfcsec.com +91-22-6171-7342

Akshay Mane

akshay.mane@hdfcsec.com +91-22-6171-7338

Macrotech Developers

New triggers emerging

Macrotech Developers Ltd (MDL) reported strong quarterly presales of INR 34.1bn (+12/-3% YoY/QoQ), with a presales volume of INR 2.6msf (+4/+0% YoY/QoQ). Average price realisation as a result increased to INR 13,115 (+8/-3% YoY/QoQ). MMR/Pune/Bengaluru market saw presales of INR 24.1/3.4/6.6bn. Collections were INR 25.9bn (-3.4/-6% YoY/QoQ). The embedded EBITDA margin on presales was ~30%. On the business development front, MDL added GDV worth INR 60bn (INR 203bn in 9MFY24, surpassing FY24 guidance of INR 175bn) and a saleable area of 2msf. The implied realisation, as a result, is INR 30,000/sq. ft. MDL saw a strong launch response for its first project in Bengaluru, selling out ~90% worth INR6.6bn with a second project likely in Q4FY24. The IRR threshold for the Bengaluru project is marked at 20%. In terms of launches, INR 63bn worth of launches are planned for the rest of FY24 with a saleable area of 4.4msf. In terms of price hikes, since Apr'23, MDL has hiked prices by 4% and expects full-year price appreciation of 6-7%. Given robust growth visibility, better-than-expected GDV addition and uptick in land prices (Palava may see price and volume increase as new infra projects get commissioned over the next few years), we increase our TP to INR 1,111/sh. Owing to the limited upside on our TP, we maintain our ADD rating.

- Q3FY24 financial highlights: Revenue: INR 29.3bn (+65/+67% YoY/QoQ, beat of 60%). EBITDA: INR 8.8bn (+118/+112% YoY/QoQ, beat of 102%). EBITDA margin: 30.1% (+736/+634bps YoY/QoQ, vs. estimate of 24%). Other income: INR 281mn (INR 1.3bn/55mn Q3FY23/Q2FY24). RPAT: INR 5.0bn (+25/+149% YoY/QoQ). Adjusted for INR 1bn of extraordinary loss on UK investment, MDL adjusted profit stood at INR 5.8bn (+44/+188% YoY/QoQ, beat of 165%). For the new sale agreements signed on/after 1st Apr 2023, MDL will follow the 'percentage of completion method (POCM)' of accounting vs. 'project completion method (PCM),' being followed for client contracts entered up to 31st March 2023. Post FY27, the entire revenue will be POCM-based.
- Robust presales, Palava to get infra connectivity boost: Presales of INR 34.1bn (+12/-3% YoY/QoQ), with a presales volume of INR 2.6msf (+4/+0% YoY/QoQ). Embedded EBITDA margin on presales: ~30%. The company launched projects of 3msf with GDV potential of INR 50bn across MMR, Bengaluru and Pune (6.6msf, INR 88.5bn in 9MFY24). New launches contributed ~25% to Q3FY24 presales. With infra connectivity expected to improve, Palava may see better pricing and volumes. Airoli-Katai connector may reduce travel time to ~25min. Besides, the upcoming bullet train station near Palava will reduce travel time to BKC by FY28.
- Net debt stable; further decline expected: Net debt is flat sequentially at INR 67.5bn. Net debt is expected to reduce further to INR 60bn by FY24-end and well within the guidance of lower net D/E of 0.5x or net debt/OCF of 1x. In terms of business development, MDL has exceeded FY24 BD guidance of INR 175bn with INR 203bn worth of projects added so far in 9MFY24. MDL has taken INR 50bn of fundraising approval from the board for growth opportunities.

YE March (Rs mn)	3QFY24	3QFY23	YoY (%)	2QFY24	QoQ (%)	FY23	FY24E	FY25E	FY25E
Net Sales	29,306	17,738	65.2	17,496	67.5	94,704	103,725	119,419	146,845
EBITDA	8,827	4,038	118.6	4,161	112.1	20,661	26,034	31,210	43,622
APAT	5,839	4,050	44.2	2,028	187.9	12,183	17,088	20,202	32,605
Diluted EPS (Rs)	6.1	4.2	44.2	2.1	187.9	12.6	17.7	21.0	33.8
P/E (x)						81.8	58.3	49.3	30.6
EV / EBITDA (x)						51.7	40.4	33.1	23.0
RoE (%)						13.5	12.8	13.6	19.1

Source: Company, HSIE Research



ADD

CMP (as on 29 Jan 20)24) I	NR 1,034
Target Price	I	NR 1,111
NIFTY		21,738
KEY CHANGES	OLD	NEW
Rating	ADD	ADD

Price Target	1	NR 977	INR 1,111
EPS Change	FY24E	FY25E	FY26E
%	-	-	-

KEY STOCK DATA

Bloomberg code	LODHA IN
No. of Shares (mn)	965
MCap (INR bn) / (\$ mn)	997/12,197
6m avg traded value (INR	mn) 1,316
52 Week high / low	INR 1,228/356

STOCK PERFORMANCE (%)

	3M	6M	12M
Absolute (%)	40.3	38.5	104.5
Relative (%)	26.3	30.6	85.0

SHAREHOLDING PATTERN (%)

	Sep-23	Dec-23
Promoters	74.93	74.92
FIs & Local MFs	3.50	3.21
FPIs	20.52	21.09
Public & Others	1.05	0.78
Pledged Shares	-	-
Source : BSE		

Parikshit D Kandpal, CFA parikshitd.kandpal@hdfcsec.com +91-22-6171-7317

Marico

Resilient margin performance

Marico's consolidated revenue fell 2% YoY as price cuts continue to impact revenue growth. Domestic revenue is down 3% with volume growth of 2% (5% four-year CAGR). Corrective steps taken to alleviate RoI challenges faced by channel partners impacted volumes in Q3. While rural demand and mass segments continued to remain soft, urban demand sustained its moderate growth trajectory. The international business posted 6% CC (2% reported) dragged by transient macro headwinds in Bangladesh as other regions delivered resilient performances. Softening inflation and a favourable mix enabled GM expansion of 635bps YoY to 51.3%, a part of which was reinvested through higher A&P spending (up 12% YoY). As a result, EBITDA grew by 13% YoY while margins expanded by 270bps to 21%. Marico remains on track for an EBITDAM expansion of 250bps in FY24. With improving macros and the anniversary of price cuts on the horizon, we continue to build in gradual recovery in volumes in coming quarters. We model a 12% EBITDA CAGR during FY23-26E. We prefer Marico, given its thrust to drive growth in its core brands, initiatives to drive D2C/foods, and the margin upcycle. We value the stock at 45x on Dec-25 EPS to derive a target price of INR 650. Maintain ADD.

- In-line revenue performance: Consolidated revenue fell 2% YoY (in line with HSIE with domestic revenue falling 3%. Domestic volume grew 2%. Growth was led by foods (+18%) owing to higher urban salience and penetration while mass HPC categories, just like rural markets, saw soft demand. PCNO value/volume growth was flat/3% YoY while VAHO value growth was 3%. Saffola revenue fell c26% YoY while volumes declined by mid-single digits. We estimate revenue will grow at a CAGR of 6% over FY23-26E.
- Bangladesh drags international performance: International business saw 6% YoY CC growth as an otherwise resilient performance was dragged by transient macro headwinds in Bangladesh. Bangladesh saw a 6% CC decline, while South-East Asia/MENA/South Africa saw CC growth of 4/26/33% YoY.
- Margin improvement sustains: Aided by softening inflation and a better mix, GM expanded 635bps YoY to 51%. Copra prices stayed at lower levels with an upward bias, while rice bran oil/LLP/HDPE exhibited a downward trend. Employee/adv/other expenses grew by 18/12/7% YoY. EBITDA margin expanded by 270bps YoY to 21%. EBITDA grew 13% YoY. Domestic/international EBIT grew by 11/16% YoY. We expect the margin to sustain recovery and build in 21-22% EBITDA margins for FY24/25/26E. We model an EBITDA CAGR of 12% for FY23-26E.
- Con call takeaways: (1) Rural demand remains soft. Urban sustaining steady improvement. FMCG sector volumes to see a gradual recovery in CY2024. (2) PCNO gained ~40bps market share. Volume improvement to sustain. (3) Digital first portfolio clocked an exit ARR of INR 4bn+ in Q3. (4) 75% of the portfolio continues to gain/maintain market share. (5) Revenue share of foods & premium personal care was at 20% of domestic business.

Quarterly/annual financial summary (INR mn) Q3FY24 Q3FY23 YoY (%) Q2FY24 QoQ (%) FY22 FY23 FY24E FY25E 24,220 24,700 24,760 (2.2) 95,378 97,473 1,07,041 1,16,734 Net Sales (1.9)97.640 EBITDA 5,130 4,560 12.5 4,970 3.2 16,810 18,100 20,475 23,019 14,947 3,530 8.5 12,260 13,020 16,882 APAT 3.830 3.280 16.8 2.97 2.54 2.748.5 9.5 EPS (INR) 16.8 10.111.6 13.1 P/E(x)54.4 51.2 44.6 39.5 EV / EBITDA 39.7 36.8 32.6 29.0 (x) 58.7 53.1 59.9 RoCE (%) 67.3 Source: Company, HSIE Research

 HDFC securities Click. Invest. Grow. INSTITUTIONAL RESEARCH

ADD

CMP (as on 29 Jan 2024)		INR 517	
Target Price		INR 650	
NIFTY		21,738	
KEY CHANGES	OLD	NEW	
Rating	ADD	ADD	
Price Target	INR 650	INR 650	
	FY24E	FY25E	
EPS %	0%	0%	

KEY STOCK DATA

Bloomberg code	MRCO IN
No. of Shares (mn)	1,294
MCap (INR bn) / (\$ mn)	668/8,173
6m avg traded value (INR n	nn) 873
52 Week high / low	INR 595/463

STOCK PERFORMANCE (%)

	3M	6M	12M
Absolute (%)	(3.9)	(10.1)	2.5
Relative (%)	(17.9)	(17.9)	(17.0)

SHAREHOLDING PATTERN (%)

	Sep-23	Dec-23
Promoters	59.40	59.39
FIs & Local MFs	9.82	9.96
FPIs	25.91	25.69
Public & Others	4.87	4.96
Pledged Shares	0.00	0.00
Source : BSE		

Pledged shares as % of total shares

Varun Lohchab

varun.lohchab@hdfcsec.com +91-22-6171-7334

Paarth Gala

FY26E

25.691

19,054

14.8

35.0

26.0

75.5

paarth.gala@hdfcsec.com +91-22-6171-7336

Riddhi Shah


riddhi.shah@hdfcsec.com +91-22-6171-7359


Rating Criteria

BUY:>+15% return potentialADD:+5% to +15% return potentialREDUCE:-10% to +5% return potentialSELL:> 10% Downside return potential

Disclosure:

Analyst	Company Covered	Qualification	Any holding in the stock
Varun Lohchab	ITC, Marico	PGDM	NO
Paarth Gala	ITC, Marico	BCom	NO
Riddhi Shah	ITC, Marico	MBA	NO
Krishnan ASV	Bajaj Finance, Cholamandalam Investment and Finance Company	PGDM	NO
Deepak Shinde	Bajaj Finance	PGDM	NO
Deepak Shinde	Cholamandalam Investment and Finance Company	PGDM	YES
Akshay Badlani	Cholamandalam Investment and Finance Company	CA	YES
Akshay Badlani	Bajaj Finance	CA	NO
Harshad Katkar	Gail (India)	MBA	NO
Nilesh Ghuge	Gail (India)	MMS	NO
Akshay Mane	Gail (India)	PGDM	NO
Parikshit Kandpal	Macrotech Developers	CFA	NO







Disclosure:

Authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issue(s) or securities. SEBI conducted the inspection and based on their observations have issued advise/warning. The said observations have been complied with. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate does have/does not have any material conflict of interest.

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

Disclaimer:

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report. As regards the associates of HSL please refer the website.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from t date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066

Compliance Officer: Murli V Karkera Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully

before investing.

Registration granted by SEBL, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

HDFC securities Institutional Equities

Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013 Board: +91-22-6171-7330 www.hdfcsec.com